It's completely understandable to feel overwhelmed right now — this is a lot to navigate, and it's clear how much you care about your son. The good news is that relapsing after initial treatment, while difficult, opens the door to a range of next steps that his haematologist can guide you through.
Because his myeloma came Show Full Answer
It's completely understandable to feel overwhelmed right now — this is a lot to navigate, and it's clear how much you care about your son. The good news is that relapsing after initial treatment, while difficult, opens the door to a range of next steps that his haematologist can guide you through.
Because his myeloma came back within 3 months, it's considered an early relapse. This timing matters because it helps the doctor decide which treatments are most likely to work next. Key factors they'll consider include:
- Which drugs were used in the first round of treatment
- Whether his myeloma still responds to lenalidomide
- His overall health and fitness level
- Whether he's eligible for a bone marrow transplant Depending on those factors, common next options include three-drug combinations such as:
- DRd (daratumumab, lenalidomide, dexamethasone) — widely used with good response rates
- KRd (carfilzomib, lenalidomide, dexamethasone) — a stronger option for those in good health
- IRd (ixazomib, lenalidomide, dexamethasone) — an all-oral option, fewer clinic visits It's also worth asking the haematologist about clinical trials — many of today's most effective therapies were only available through trials just a few years ago.
Going into the appointment with questions prepared can really help. A MyMyelomaTeam member once shared this advice: *"I always ask my doctor what is on the horizon — what's coming next?"* That kind of open conversation with the medical team makes a real difference.
May 10
Join
Your Privacy Choices
